GB8813064D0
(en)
*
|
1988-06-02 |
1988-07-06 |
Euro Celtique Sa |
Controlled release dosage forms having defined water content
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5478577A
(en)
†
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
IL109460A
(en)
*
|
1993-05-10 |
1998-03-10 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL109944A
(en)
†
|
1993-07-01 |
1998-12-06 |
Euro Celtique Sa |
Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
GB9519363D0
(en)
*
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
DE19710008A1
(de)
*
|
1997-03-12 |
1998-09-17 |
Basf Ag |
Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
|
WO1999032120A1
(en)
*
|
1997-12-22 |
1999-07-01 |
Euro-Celtique, S.A. |
A method of preventing abuse of opioid dosage forms
|
EP2266564B1
(en)
|
1997-12-22 |
2013-03-13 |
Euro-Celtique S.A. |
Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
|
US6602521B1
(en)
*
|
1998-09-29 |
2003-08-05 |
Impax Pharmaceuticals, Inc. |
Multiplex drug delivery system suitable for oral administration
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
EP2295043A1
(en)
*
|
1999-10-29 |
2011-03-16 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
ES2326730T3
(es)
*
|
2000-02-08 |
2009-10-19 |
Euro-Celtique S.A. |
Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas.
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
EP2932964A1
(en)
|
2000-10-30 |
2015-10-21 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
EP1387673B1
(en)
|
2001-05-11 |
2010-12-29 |
Endo Pharmaceuticals Inc. |
Abuse-resistant controlled-release opioid dosage form
|
DK1416842T3
(da)
*
|
2001-07-18 |
2009-03-16 |
Euro Celtique Sa |
Farmaceutiske kombinationer af oxycodon og naloxon
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US20030157168A1
(en)
*
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
NZ535286A
(en)
|
2002-04-05 |
2007-07-27 |
Euro Celtique Sa |
Matrix for sustained, invariant and independent release of active compounds
|
SK286107B6
(sk)
*
|
2002-04-12 |
2008-03-05 |
Zentiva, A. S. |
Analgeticky účinný perorálny liečivý prípravok s kontrolovaným uvoľňovaním opioidnej účinnej látky a spôsob jeho prípravy
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
CA2499550C
(en)
|
2002-09-20 |
2013-10-15 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
CA2498798A1
(en)
*
|
2002-09-20 |
2004-04-01 |
Alpharma, Inc. |
Sustained-release opioid formulations and methods of use
|
ES2350689T3
(es)
|
2002-12-13 |
2011-01-26 |
Durect Corporation |
Sistema de suministro de fármacos oral que comprende materiales vehículo líquidos de alta viscosidad.
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
ES2653568T3
(es)
|
2004-06-12 |
2018-02-07 |
Collegium Pharmaceutical, Inc. |
Formulaciones de fármacos para la prevención del abuso
|
WO2006033948A2
(en)
*
|
2004-09-17 |
2006-03-30 |
Durect Corporation |
Sustained local anesthetic composition containing preferably a sugar ester such as saib
|
EP1702558A1
(en)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
RU2408368C2
(ru)
|
2005-06-27 |
2011-01-10 |
Биовэйл Лэборэториз Интернэшнл С.Р.Л. |
Препараты соли бупропиона с модифицированным высвобождением
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
US20090317355A1
(en)
*
|
2006-01-21 |
2009-12-24 |
Abbott Gmbh & Co. Kg, |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20100172989A1
(en)
*
|
2006-01-21 |
2010-07-08 |
Abbott Laboratories |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20090022798A1
(en)
*
|
2007-07-20 |
2009-01-22 |
Abbott Gmbh & Co. Kg |
Formulations of nonopioid and confined opioid analgesics
|
PT2484346T
(pt)
*
|
2006-06-19 |
2017-04-26 |
Alpharma Pharmaceuticals Llc |
Composições farmacêuticas
|
CA2671200A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophilic abuse deterrent delivery system
|
WO2008066642A2
(en)
|
2006-11-03 |
2008-06-05 |
Durect Corporation |
Transdermal delivery systems comprising bupivacaine
|
JP2011506318A
(ja)
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
経口医薬製剤
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
JP2011511782A
(ja)
|
2008-02-12 |
2011-04-14 |
アボット・ラボラトリーズ |
長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
|
US20100003322A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Lai Felix S |
Enteric coated hydrophobic matrix formulation
|
PE20110422A1
(es)
*
|
2008-07-07 |
2011-07-01 |
Euro Celtique Sa |
Composicion farmaceutica que comprende antagonistas opioides
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
TR201900199T4
(tr)
|
2009-03-10 |
2019-02-21 |
Euro Celtique Sa |
Oksikodon ve nalokson içeren çabuk salımlı farmasötik bileşimler.
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
SG10201510564PA
(en)
|
2010-12-22 |
2016-01-28 |
Purdue Pharma Lp |
Encased tamper resistant controlled release dosage forms
|
KR20140075807A
(ko)
|
2010-12-23 |
2014-06-19 |
퍼듀 퍼머 엘피 |
탬퍼 저항성 고체 경구 투여 형태
|
EP3485880A1
(en)
|
2012-04-17 |
2019-05-22 |
Purdue Pharma LP |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
US9149533B2
(en)
|
2013-02-05 |
2015-10-06 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
WO2014144975A1
(en)
|
2013-03-15 |
2014-09-18 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
MY183489A
(en)
|
2013-07-23 |
2021-02-22 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
EP3364955B1
(en)
|
2015-10-09 |
2022-04-20 |
RB Health (US) LLC |
Pharmaceutical formulation
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
EP3703724A1
(en)
|
2017-11-02 |
2020-09-09 |
NatureCeuticals Sdn. Bhd. |
Extract of orthosiphon stamineus, formulations, and uses thereof
|
JP2023515918A
(ja)
|
2020-01-13 |
2023-04-17 |
デュレクト コーポレーション |
不純物が低減された徐放性薬物送達システム及び関連の方法
|